Drug Profile


Alternative Names: CI 942; NSC 349174; Oxantrazole; PD 111815

Latest Information Update: 23 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Anthraquinones; Cytostatics; Pyrazoles; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Breast cancer; Endometrial cancer; Gastric cancer; Malignant melanoma

Most Recent Events

  • 12 Jul 2000 Profile reviewed but no significant changes made
  • 22 Jun 2000 Warner-Lambert has merged with Pfizer
  • 27 Aug 1998 Profile reviewed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top